a, b, EFOX-D5 levels in RAW264.7 activated and treated with the indicated inhibitors at the following concentrations: genistein (25 μM), MAFP (25 μM), MK886 (500 nM), ETYA (25 μM), OKA (50 nM), ASA (200 μM), indomethacin (25 μM), ibuprofen (100 μM), diclofenac (1 μM) and NS-398 (4 μM). ND indicates not detectable. Data are expressed as mean ± S.D. (n=4), where * = significantly different (p<0.01) from “Kdo2 + IFNγ” (one-way ANOVA, post-hoc Tukey’s test). c, Temporal formation of hydroxy-precursors (MRM 345/327) of EFOX-D5 synthesized in vitro by purified ovine COX-2 + DPA ± ASA. d, e, Chromatographic profiles (left panels) and spectra (right panels) of the two isomers formed by COX-2 ± ASA. f, BME-adducted 17-EFOX-D5 standard (MRM 421.2/343.2) and EFOX-D5 BME-adducts from activated RAW264.7 cells ± ASA. g–i, Production of EFOX-D5 and OH-DPA by RAW264.7 cell lysates supplemented with OH-DPA, DPA, or vehicle alone. Full and empty symbols indicate activated and non-activated cell lysates respectively.